Health Series Number 27

Cancer in the Australian Capital Territory 1994 – 1998

Population Health Research Centre ACT Department of Health and Community Care

February 2002

ACKNOWLEDGEMENTS

This report has been made possible by the co-operation of staff at hospitals, nursing homes and pathology laboratories throughout the ACT. The work of all people concerned is appreciated and thanks are extended to them for their continued support in notifying cancer cases.

The majority of death data contained in this publication has been obtained from the ACT Registrar of Births, Deaths and Marriages. The Australian Bureau of Statistics supplies population and demographic data and also coded death data. Our thanks are extended to the Australian Institute of Health and Welfare and the National Death Index for their help with matching of death data and duplicate registrations. Special thanks to all the other State and Territory Registries' for their assistance in resolving interstate duplications and to the Australasian Association of Cancer Registries for their support.

We would also like to acknowledge the staff of the New South Wales Central Cancer Registry for their continued support and assistance. The data for this report comes from the New South Wales Cancer Registry. The ACT Cancer Registry performed the analyses and prepared the full report.

ISSN 1325-1090

© Australian Capital Territory, Canberra, March 2002

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced without written permission from Library and Information Management, Department of Urban Services, ACT Government, GPO Box 249, Civic Square ACT 2608. You may download, display, print and photocopy this material in part or in whole, in unaltered form only for your non-commercial personal or organisational use.

Produced for the ACT Department of Health and Community Care by the Population Health Research Centre and printed by Publishing Services on recycled paper.

ACT Cancer publications in the Health Series can be accessed on the Internet via http://www.health.act.gov.au/healthinfo/

Enquiries about this publication should be directed to Barbara Stuart-Harris, Manager, ACT Cancer Registry, Population Health Research Centre, The Canberra Hospital, PO Box 11 Woden ACT 2606 or via email barbara.stuartharris@act.gov.au

Publication No 02/0438

ACT Government telephone: Canberra 13ACT1 or 132281 Homepage at http://www.act.gov.au

CONTENTS

1.	Introduction4
2.	Structure of this Report5
3.	Trends in Cancer Incidence and Mortality in the ACT6
4	Leading Cancer Sites Incidence 1994-1998
5.	Leading Cancer Sites by age and sex, Incidence 1994-1998 14
6.	Demography15
7.	Cancer Services in the ACT17
8.	Incidence Tables 1994-1998 20
9.	Mortality Tables 1994-199739
10	. Terminology used56
11	. References 57

INTRODUCTION

Establishment of the Cancer Registry

The ACT Cancer Registry was established in July of 1994, when cancer reporting became mandatory in the ACT. Prior to this, the NSW Cancer Registry had been collecting notifications provided voluntarily on cancer in the ACT since 1972.

This report is the third produced by the ACT Cancer Registry. However, it represents the first opportunity for the Registry to publish reliable statistics since the introduction of mandatory reporting.

Four Hospitals, three Day Surgeries, seven Nursing Homes and four Pathology Laboratories notify cancer to the registry. These are all paper notifications, with the exception of the Department of Radiation Oncology at The Canberra Hospital, which notifies electronically. The NSW Cancer Registry is contracted to process and code notifications, providing the ACT Cancer Registry with data on all newly reported cases of cancer. The size of the ACT population, its geographical location and a considerable cross-border use of medical services between ACT and NSW residents, makes this arrangement cost effective and efficient.

Currently, the latest data available in the ACT Cancer Registry are for 1999. More recent data are not available because notification and data processing takes an average of 18 months. A considerable amount of time and effort is spent matching, classifying and checking cases to ensure completeness.

ACT Cancer Registry (2001)

Bruce Shadbolt Director

Barbara Stuart-Harris Manager

Maureen Bourne Data Manager

STRUCTURE OF THIS REPORT

This report documents incidence data for the ACT during the period 1 January 1994 and 31 December 1998 as they stood in August 2000. As a result of the process involved in receiving and checking death data, reporting for mortality is complete to the end of 1997. As well as overall incidence and mortality rates, those for individual cancer sites are reported according to the International Classification of Diseases, 9th Revision (ICD-9) and the histology to the International Classification of Diseases for Oncology (ICD O Second Edition).

Despite this being the third report produced by the ACT Cancer Registry, findings between reports cannot easily be compared because previous reports relied on voluntary notifications (1982 - 1991 and 1983 – 1992).

Incidence Data

Cancer incidence by site is defined in this publication as the number of primary cancers diagnosed in people resident in the ACT between 1 January 1994 and 31 December 1998. There are 274 cases of multiple primaries recognised in the ACT incidence data.

When a specific cancer site is not examined, only the first diagnosis for an individual is counted.

In general, five-year averages are examined throughout this report to improve the reliability of estimates from small numbers.


Mortality Data

Cancer mortality is defined in this publication as the number of people resident in the ACT when diagnosed with cancer, who died from cancer between 1 January 1994 and 31 December 1997.

Data on deaths from cancer are obtained from the ACT Registrar of Births, Deaths and Marriages. These data are linked to the database for identification of dates and cause of death. Matching of deaths outside the ACT with ACT residents diagnosed with cancer is done through the Australian Institute of Health and Welfare, National Death Index.

RECENT TRENDS IN ACT INCIDENCE AND MORTALITY

The estimated lifetime risk of cancer for Australia in 1997 was 1 in 3 for men and 1 in 4 for women. (1) These lifetime risks are the same as those for the ACT. The age-standardised incidence rise for males from 1994 to 1995 (Figure 1) mostly reflects a significant increase in the notification of prostate cancers (Figure 2b). The trend is indicative of an increase in screening by medical services (eg PSA Testing). The fall after 1996 is mostly attributed to the stabilisation of the identification of prostate cases and a decline in the number of PSA tests conducted (a national experience). The incidence rate trend in the ACT is similar to the Australian average, although the rise and fall for Australia started in the early 1990's with the ACT showing a significant lag. Most of the lag reflects a delayed take up by medical services in screening tests for prostate cancer since there is some controversy associated with PSA testing. Also, the incidence rate of prostate cancer in the ACT is higher than the Australian average (Figure 2b).



Source: ACT Cancer Registry and Cancer in Australia Series 1994-1997, AIHW & AACR


Figure~1:~ACT~and~Australian~trends~in~age-standardised~incidence~rates~for~all~cancers~(excluding~non-melanocytic~skin~cancers)~by~sex


In addition to prostate cancer cases, the rise and fall of the age-standardised male incidence rate is largely affected by a rise in the rate of colo-rectal cancer and melanoma of the skin (Figure 3a & 3c), being similar to the Australian trend, and a decline in the rate of lung cancer (Figure 3b). The Act's age-standardised incidence rate of lung cancer follows a similar trend to the Australian average, but the rates are much lower. This difference reflects the healthy lifestyles of ACT males and the predominantly white-collar labour force.

The age-standardised incidence rates for females over the five-year period show a decline (Figure 1). Given their large incidence, breast and colo-rectal cancers have contributed mostly to the trend. Age-standardised breast cancer rates between 1994 and 1998 produce a 'U' shape (Figure 2a). This is a similar trend to the Australian average, although the ACT rates tend to be higher earlier in the period. The age-standardised incidence rate of colo-rectal cancer for females is falling (Figure 3a). This decline is compared to the relatively steady Australian rates.

The female age-standardised incidence rates of lung cancer and melanoma also significantly contribute to the female trend by tempering the overall decline in incidence rates. Like the Australian average, ACT females have increased in the age-standardised incidence rates over the five-year period (Figures 3b & 3c). The ACT rates are somewhat unstable because of small numbers, but on average the trend is rising.

Incidence rates for breast and prostate cancers







Source: ACT Cancer Registry and Cancer in Australia series 1994-1997, AHIW & AACR

Figure 2: Trends in age standardised rates for (a) breast cancer and (b) prostate cancer, Australia and ACT, 1994 - 1998


Incidence rates for colorectal, lung and melanoma skin cancers








3c: Melanoma of the Skin



Source: ACT Cancer Registry and Cancer in Australia Series 1994-1997, AIHW & AACR

Figure 3: Trends in age standardised rates for (a) colorectal cancer (b) lung cancer and (c) melanoma of the skin, Australia and ACT, 1994 - 1998

In relation to mortality, the small numbers produce vacillating trends over time for both males and females (Figure 4). Generally however, the age-standardised cancer mortality rates for males are tending to fall. The overall trend is similar to the Australian average, although the national rates are more stable. The main contributors to the ACT male downward trend are prostate, lung and colorectal cancers. Both prostate and lung cancer death rates are generally below the Australian average (Figures 5b & 5d), while colorectal mortality rates tend to be slightly higher (Figure 5c).




Source: ACT Cancer Registry and Cancer in Australia Series 1994-1997, AIHW & AACR

Figure 4: ACT and Australian Trends in age-standardised mortality rates for all cancers (excluding non-melanocytic skin cancers) by sex

For females, there is no clear rise or fall in age-standardised mortality rates between 1994 and 1997 (Figure 4). On the other hand, the Australian average has fallen slightly over this period. The main causes of death contributing to these trends are breast, colorectal and lung cancers (see Figures 5a, c & d). It is difficult to describe the trend for each of these causes in the ACT, although for colorectal and lung cancer deaths the ACT rates tend to be below or at the national average, while the ACT breast cancer rates tend to be slightly above the Australian average.

In addition to females having lower age-standardised incidence and mortality rates than males for both the ACT and Australia, another major difference is that females have increased their incidence and mortality rates associated with lung cancer, while rates for males have fallen. This trend mostly reflects a change in the smoking habits of men and women. Twenty-five years ago smoking rates for Australian men were almost double those in women. Now estimates suggest that 25% of men and 20% of women aged over 14 years currently smoke. Thus, the changes in men's and women's smoking habits over the last two decades towards a smaller proportion of men smoking and a rising proportion of women smoking has contributed to the narrowing gap between men's and women's lung cancer rates.

Mortality rates for breast, prostate, colorectal and lung cancers



Source: ACT Cancer Registry and Cancer in Australia series, 1994-1997, AIHW & AACR

0-

Figure 5: Trends in age-standardised mortality rates for (a) breast, (b) prostate, (c) colorectal and (d) lung cancers, Australia, 1994-1997

ACT CANCER INCIDENCE SUMMARY 1994-1998

Age

- The incidence of cancer is age dependent.
- Less than 1% of all cancers occur before the age of 15 years, the most common being leukaemia and lymphoma.
- 58% of cancers occur in persons aged over 65 years.
- Melanoma, testis and breast cancers account for the majority of new cancers in persons under the age of 45 years.
- The age at which ACT residents are diagnosed with cancer has remained relatively constant between 1994 and 1998, with the average age for males being 63 years and for females 60 years.

Sex

- More males (322 per 100,000) than females (245 per 100,000) are diagnosed with cancer (age-standardised rates).
- This relationship exists for the vast majority of cancer sites. The main exceptions are breast cancer and cancer of the thyroid gland.

Leading Sites

- The leading four sites account for 64% of new cancers in males and 62% of new cancers in females.
- For males, these are prostate (32%), colon and rectum (13%), melanoma of the skin (11%) and lung (8%).
- For females, these are breast (33%), colon and rectum (12%), melanoma of the skin (10%) and lung (7%).
- The four most common sites overall (55% of all new cancers) are prostate (17%), breast (15%), colon and rectum (13%) and melanoma of the skin (10%).

Prostate Cancer

- Has risen from the fourth most commonly diagnosed cancer prior to 1987 to the most common.
- 804 new cases of prostate cancer were diagnosed in men between 1994 and 1998, ranging from 122 cases in 1994 to 156 in 1997.
- This increase most likely reflects an increased use of PSA tests and transrectal ultrasonography.

Lung Cancer

- Remains the fourth most common site in females since 1988.
- Newly diagnosed cases of lung cancer in women have risen from 25 in 1994 to 34 in 1998, reflecting the national trend. (1)
- Dropped to the fourth most common cancer among males between 1994-1998.
- Fifth most common site overall accounting for 7% of all new cancers.

Breast Cancer

- Remains the most commonly diagnosed site for new cancers in females.
- 723 new cases diagnosed between 1994-1998.
- Accounts for 33% of all cancers in females diagnosed between 1994-1998.
- Second most common site overall (15% of all cancers).
- Most commonly diagnosed cancer between the ages of 30 and 59 years.

Colorectal Cancer

- Remains the second most commonly diagnosed site of cancer in females since 1992.
- Dropped to the second most common site for males in 1994-1998.
- The third most common site overall accounting for 13% of all new cancers.

Melanoma of the Skin

- Melanoma is the third most common site of new cancers for each sex.
- Fourth most common cancer overall.
- Accounts for 10% of all new cancers.
- Melanoma is more prevalent in the younger age groups (ie. under 44 years of age).
- Relatively high incidence rate (30 per 100,000) compared to the death rate (3 per 100,000).

ACT CANCER MORTALITY SUMMARY 1994-1997

- Cancer is the second most common cause of death after circulatory disease in the ACT.
- Cancer is responsible for 29% of all deaths in the ACT between 1994 and 1997 (Circulatory disease accounts for 39%).
- 1527 ACT residents died from cancer between 1994 and 1997.

Sex

- 824 male deaths (147 per 100,000) and 703 female deaths (100 per 100,000) between 1994 and 1997 (age-standardised rates).
- This higher rate for males holds for the vast majority of causes. The main exception being breast cancer.
- Most common causes in males are lung (16%), colorectal (15%) and prostate (9%) cancers.
- Most common causes in females are breast (21%), colorectal (12%) and lung (10%) cancers.

Breast

- Breast cancer remains the leading cause of death in females (22 per 100,000).
- The third most common cause of death overall, accounting for 9%.

Colorectal

- Remains the second most common cause of death in both sexes since 1983.
- The leading cause of death overall between 1994 and 1997, accounting for 14% of all deaths.

Prostate

- Remains the third most common cause of death in males since 1983.
- Relatively high incidence rate (116 per 100,000) compared to death rate (16 per 100,000).

Lung

- Lung cancer has remained the leading cause of death in males since 1983 and the third most common cause in females.
- Males (22 per 100,000) have a significantly higher rate of mortality from lung cancer than females (10 per 100,000).
- It is the second most common cause of death overall accounting for 13% of all deaths.

LEADING CANCER SITES IN THE ACT

Incidence 1994-1998

Male - Incidence

Site	Cases 5 yrs	CR	ASR	% of total
Prostate	804	104.9	115.8	32
Colon or Rectum	336	43.9	46.3	13
Melanoma	274	35.8	34.6	11
Lung	196	25.6	26.9	8
Lymphoma	116	15.1	14.9	5
Unknown	95	12.3	13.1	4
Bladder	75	9.8	10.7	3
Kidney	70	9.1	9.0	3
Stomach	65	8.5	9.1	3
Testis	60	7.8	6.3	2

Female - Incidence

Site	Cases 5 yrs	CR	ASR	% of total
Breast	723	94.8	85.2	33
Colon or Rectum	260	34.1	29.7	12
Melanoma	213	27.9	25.0	10
Lung	147	19.3	17.7	7
Lymphoma	120	15.7	14.3	5
Uterus	83	10.9	10.6	4
Unknown	72	9.4	7.3	3
Ovary	67	8.8	8.2	3
Cervix	65	8.5	7.0	3
Leukaemia	57	7.5	7.4	3

Persons - Incidence

Persons – Incluence				
Site	Cases	CR	ASR	% of
	5 yrs			total
Prostate	804	104.9	115.8	17
Breast	730	47.7	44.0	15
Colon or Rectum	596	39.0	378	13
Melanoma	487	31.9	29.5	10
Lung	343	22.4	21.8	7
Lymphoma	236	15.4	14.4	5
Unknown	167	10.9	10.1	4
Leukaemia	111	7.3	7.3	2
Kidney	110	7.2	6.7	2
Stomach	107	7.0	6.8	2

The percentages are based on the number of cases of cancer.

Mortality 1994-1997

Male - Mortality

Site	Cases 4 yrs	CR	ASR	% of total
Lung	128	20.9	22.4	16
Colon or Rectum	124	20.2	22.7	15
Prostate	87	14.2	16.4	9
Unknown	60	9.8	11.1	7
Lymphoma	42	6.9	7.2	5
Leukaemia	41	6.7	7.0	5
Stomach	38	6.2	6.9	5
Pancreas	33	5.4	6.2	4
Brain	30	4.9	5.1	4
Bladder	28	4.6	5.0	3

Female - Mortality

Site	Cases 4 yrs	CR	ASR	% of total
_	·			
Breast	145	23.8	21.8	21
Colon or Rectum	87	14.3	12.4	12
Lung	71	11.7	10.0	10
Unknown	47	7.7	5.9	7
Lymphoma	40	6.6	5.8	6
Ovary	30	4.9	4.4	4
Stomach	28	4.6	3.6	4
Pancreas	28	4.6	3.9	4
Leukaemia	22	3.6	3.2	3
Brain	21	3.5	2.9	3

Persons - Mortality

Site	Cases 4 yrs	CR	ASR	% of total
Colon or Rectum	211	17.3	17.2	14
Lung	199	16.3	15.6	13
Breast	145	23.8	21.8	9
Unknown	107	8.8	8.4	7
Prostate	87	14.2	16.4	6
Lymphoma	82	6.7	6.3	5
Stomach	66	5.4	4.9	4
Leukaemia	63	5.2	5.0	4
Pancreas	61	5.0	4.8	4
Brain	51	4.2	3.9	3

CR = Crude Rate ASR = Age-standardised rate (world)

LEADING SITES FOR CANCER INCIDENCE IN THE ACT BY AGE GROUP AND SEX 1994-1998

For each age group and sex the top ranking new cancer sites between 1994 and 1998 are included. The percentage of total new cancers in that age group is shown along with the number of cases.

ALL CANCER

Male	
0-14	24
15-29	72
30-44	198
45-59	593
60-74	1122
75+	530
Female	
Female 0-14	21
	21 75
0-14	
0-14 15-29	75
0-14 15-29 30-44	75 295
0-14 15-29 30-44 45-59	75 295 713

ALL Cancer

Number of Cases

2539
2193
4732

Mortality

Male	824
Female	703
Persons	1527

There are 100 cases where cause of death is unknown.

NHL = Non-Hodgkins Lymphoma

MALE

FEMALE

0-14 years

Site	Cases 5 yrs	% of age group
Leukaemia	5	21
NHL	3	13

0-14 years

Site	Cases	% of age
	5 yrs	group
Leukaemia	9	43
Brain	3	14
Hodgkins Disease	3	14

15-29 years

16	22
12	17
8	11
7	10
4	6

15-29 years

Melanoma	22	29
Hodgkins Disease	10	13
Thyroid Gland	9	12
Cervix	5	7
Bone	4	5

30-44 years

eo ii jears		
Melanoma	53	27
Testis	32	16
Colon or Rectum	21	11
NHL	11	6
Brain	10	5

30-44 years

Breast	128	43
Melanoma	49	17
Cervix	25	8
Thyroid Gland	16	5
Colon or Rectum	15	5

45-59 years

Prostate	130	22
Colon or Rectum	106	18
Melanoma	99	17
Lung	36	6
NHL	30	5

45-59 years

Breast	320	45
Colon or Rectum	76	11
Melanoma	75	11
Ovary	34	5
Lung	29	4

60-74 years

464	41
147	13
93	8
84	7
43	4
	147 93 84

60-74 years

Breast	192	29
Colon or Rectum	88	13
Lung	70	11
Melanoma	44	7
Uterus	39	6

75+ years

Prostate	208	39
Colon or Rectum	58	11
Lung	58	11
Melanoma	24	5
Unknown	24	5

75+ years

Colon or Rectum	80	18
Breast	79	18
Lung	39	9
Unknown	37	9
NHL	24	6

DEMOGRAPHY

Source: ABS Population by age and sex, Australian States and Territories, Cat. No 3201




Figure 6: Australian Capital Territory 1998. Estimated percentage age distribution, males and females, ACT 1998

Population

There has been a small but constant growth in the ACT population over the last 10 years. The estimated population in 1996 was 307,511, which represents a growth of 6.8% since the 1991 census. Population growth has slowed in the last five years. (2)

Table 1:Estimated population, by sex, ACT, 1988-1998

Sex	1988	1992	1996	1998
Male	137,321	147,404	155,198	153,537
Female	136,213	146,755	152,313	154,874
Persons	273,534	294,159	307,511	308,411

Source: Estimated Resident Population by Sex and Age States and Territories of Australia June 1988 to June 1996, ABS Cat. No. 3201.0

ABS: Population by age and sex, Australian States and Territories, Cat No. 3201

Table 2: Estimated Population of the ACT, 1998

AGE	MALES	FEMALE	PERSONS
0-4	10,781	10,396	21,177
5-9	11,343	10,798	22,141
10-14	11,307	10,873	22,180
15-19	12,821	11,745	24,566
20-24	14,309	13,264	27,573
25-29	13,146	13,325	26,471
30-34	11,930	12,287	24,217
35-39	12,307	12,804	25,111
40-44	11,662	12,349	24,011
45-49	11,620	12,191	23,811
50-54	10,279	10,003	20,282
55-59	6,749	6,508	13,257
60-64	4,816	4,776	9,592
65-69	3,772	3,947	7,719
70-74	3,004	3,618	6,622
75-79	2,113	2,878	4,991
80-84	1,011	1,726	2,737
85+	567	1,386	1,953
TOTAL	153,537	154,874	308,411

The 1996 census confirms that the ACT has a higher socioeconomic profile compared to the rest of Australia. The ACT has considerably more activity than the national average in public employment and higher education.

Age and Sex

The ACT population is younger than Australia generally with a median age of 31.3 years in June 1996, compared to 34.0 years for the Australian population. (3) This is reflected in the population composition. Twenty-two per cent of the ACT population is aged 0-14 years (Australia has 21%)⁽⁴⁾ and only 7.3 percent aged 65 years and over (Australia has 12%). The populations of the ACT and Australia are ageing quite rapidly but while other States will roughly double their proportion of people aged over 65 years, the ACT proportion is expected to nearly triple between now and 2051⁽⁴⁾ In both the ACT and Australia, the majority of people aged greater than 65 years are female, becoming more marked as age increases.

The Environment

The ACT was established as the seat of National Government in 1911 and became a self-governing territory in 1989. It covers an area of approximately 2400km² and is surrounded on all sides by New South Wales. (5) Consequently, the ACT provides substantial services to the surrounding NSW South East Region as well as to its own residents.

Almost all ACT residents live in metropolitan Canberra, while 85% of the Territory's land mass is devoted to national parks, nature reserves, pine plantations and properties. The ACT has no heavy industries and enjoys good air and water quality.

Birthrate

The crude birth rate is slowly declining. There were 2,155 female and 2,241 male births registered to mothers normally resident in the ACT in 1996. This represents an increase of 7.2 % since 1986 (Australian increase was 4.3%). (6) The fertility rate stands at around 1.6 children per woman (1997) compared to the 1996 Australian rate of 1.8. The ACT fertility rate is the lowest of all the States and Territories. (8)

Ethnicity

The 1996 census showed that 25.7% of the ACT population was born overseas, compared to 26.1% of the Australian population as a whole (9), one third of these coming from the United Kingdom, Ireland and New Zealand. The remaining two thirds are mainly from Europe and the former USSR with a smaller Asian component.

Aboriginal and Torres Strait Islander Population

There were 1,593 people who identified as being Indigenous in the 1991 census and 2,898 in 1996. This represents an increase of 81.9%, which is probably due more to willingness to self-identify than a dramatic increase in migration (3)

The Aboriginal and Torres Strait Islander community in the ACT has the highest level of education and labour force participation rates of all indigenous people in Australia. Forty-two percent of Aboriginal families in the ACT have a non-Aboriginal mother compared to a national figure of thirty percent. (10)

CURRENT ARRANGEMENTS FOR THE PROVISION OF CANCER SERVICES IN THE ACT⁽¹¹⁾

Health Promotion and Primary Prevention

Health promotion activities related to cancer are generally integrated with general lifestyle, nutrition and healthy lifestyle programs offered through the ACT Community Care, Healthpact sponsorship and non-government organisations, particularly the Cancer Council ACT.

Cancer Council ACT

Formed in 1976, the Cancer Council ACT is a not for profit non-government organisation that aims to reduce the incidence and impact of cancer in the Canberra region. The Society offers information and support to people with cancer and their carers. Key health promotion activities include:

- The Cancer Information Service.
- The QUIT Program and other health promotion/prevention activities.
- Provision of research grants from donations received for this purpose, for a range of research activities.

General Practitioners

The ACT Division of General Practice provides continuing education programs in cancer prevention and early detection and is actively involved in the ACT Breast Cancer Treatment Group.

A group of ACT GPs provide palliative care services in association with the ACT Hospice and act as consultants for palliative care nursing services in the community.

Population Screening for Early Detection of Cancer

BreastScreen ACT

BreastScreen ACT is administered as part of a comprehensive Women's Health Program by ACT Community Care. Participation rates by women in the age group 45-64 years appear high by national standards.

ACT Breast Cancer Treatment Group

In the ACT, a multidisciplinary Breast Cancer Treatment Group has reviewed the NHMRC guidelines and developed agreed care pathways and monitoring and review mechanisms that conform to the spirit of the guidelines.

Cervical Cancer Screening

In 1991 the National Cervical Cancer Screening Program was established. ACT women appear to have high rates of cervical screening compared with the rest of Australia.

Cancer Treatment Services

The Canberra Hospital (TCH)

TCH is the principal care provider in the ACT and offers expertise in surgery, medical oncology, radiation oncology and haematology services.

Outreach Services

Services for residents of Southern NSW make up between 25-40% of all referrals. Medical oncologists provide services at Moruya, Bega and Goulburn and radiation oncologists visit Moruya and Bega.

Calvary Public Hospital

Surgery is the main form of cancer care provided at Calvary Public Hospital with a significant portion of ACT breast cancer surgery being undertaken there. General Physicians supervise chemotherapy for selected cancer patients and therapy is provided in an outpatient clinic managed by a nurse trained in oncology.

Private Hospitals

John James Memorial Hospital is the major provider of cancer care in the private sector.

The National Capital Private Hospital has a small oncology unit managed by oncology trained nurses.

Continuing Care Services

ACT Community Care uses a combination of generalist and specialist community nurses to provide the bulk of continuing cancer care in the community.

Non-Government Cancer Support Groups

a. ACT Cancer Society Support Groups

For example: KidsCan, Partners Groups, Breast Cancer Support Group, Prostate Cancer Support Group

b. ACT Eden – Monaro Cancer Support Group

This group provides information, support and activities for children diagnosed with cancer.

c. Respite and Carer Support Services

- ACT Respite Care: Integrated, in home support and home based respite funded under the HACC and Disability Program.
- Canberra Institute of Technology: Training to unpaid carers.
- **FABRIC**: Home based respite care.

- **KINCARE**: Integrated in-home support and respite care.
- Carers Association: Information and counselling for carers.

d. ACT Hospice and Palliative Care Association.

e. Oncology Services Consumer Group

A group formed in 1994 by people who have received cancer treatment in the ACT. It aims to provide a voice for consumer services and provide information, support, education and advocacy for improvement in cancer care.

Palliative Care

Palliative care is increasingly recognised as a specialist stream. Palliative care services are well established and supported in the ACT

TABLES

CANCER INCIDENCE IN THE ACT

by age, sex and site 1994 - 1998

Age Yrs 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Total CR ASR 95% CI Life Risk

Males	10	5	9	8	29	31	39	54	98	135	177	258	294	356	372	251	148	80	2354				
Rate	17.8	8.8	15.9	12.8	37.1	47.0	61.1	87.3	166.0	229.4	398.5	837.1	1303.4	1948.4	2563.4	2881.4	3328.1	3301.7		307.2	322.2	(309.2 - 335.	2)
Females	10	3	8	11	22	42	53	96	145	220	242	219	167	216	235	167	133	115	2104				
Rate	18.5	5.6	14.8	18.4	30.0	64.8	83.9	152.1	237.5	372.6	567.0	748.4	766.0	1121.8	1325.3	1332.2	1719.9	1968.8		275.8	245.0	(234.5 – 255.4)
Persons	20	8	17	19	51	73	92	150	243	355	419	477	461	572	607	418	281	195	4458				
Rate	18.1	7.2	15.4	15.5	33.7	55.8	72.46	120.0	202.3	301.1	481.1	793.9	1039.3	1524.3	1882.5	1967.3	2307.1	2359.6		291.6	278.4	(270.2 – 286.5)
140	Malign	ant n	eopla	sm of	lip																		
Males	0	0	0	0	0	2	2	0	0	3	1	5	4	3	3	1	0	0	24				
Rate	0.0	0.0	0.0	0.0	0.0	3.0	3.1	0.0	0.0	5.1	2.3	16.2	17.7	16.4	20.7	11.5	0.0	0.0		3.1	3.2	(2.2 - 4.8)	23
Females	0	0	0	0	0	0	0	0	0	1	2	1	2	3	2	1	2	0	14				
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	4.7	3.4	9.2	15.6	11.3	8.0	25.9	0.0		1.8	1.7	(1.0 - 2.9)	43
Persons	0	0	0	0	0	2	2	0	0	4	3	6	6	6	5	2	2	0	38				
Rate	0.0	0.0	0.0	0.0	0.0	1.5	1.6	0.0	0.0	3.4	3.4	10.0	13.5	16.0	15.5	9.4	16.4	0.0		2.5	2.5	(1.8 - 3.4)	30
141	Malign	ant n	eopla	sm of	tongu	ie																	
Males	0	0	0	0	0	1	0	1	0	0	3	0	1	3	2	1	1	0	13				
Rate	0.0	0.0	0.0	0.0	0.0	1.5	0.0	1.6	0.0	0.0	6.8	0.0	4.4	16.4	13.8	11.5	22.5	0.0		1.7	1.7	(1.0 - 3.0)	45
Females	0	0	0	0	0	1	0	0	0	2	0	0	0	1	1	0	1	1	7				
Rate	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	3.4	0.0	0.0	0.0	5.2	5.6	0.0	12.9	17.1		0.9	0.7	(0.4 - 1.6)	126
Persons	0	0	0	0	0	2	0	1	0	2	3	0	1	4	3	1	2	1	20				
Rate	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.8	0.0	1.7	3.4	0.0	2.3	10.7	9.3	4.7	16.4	12.1		1.3	1.2	(0.8 - 1.9)	67

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
142	Malign	ant 1	neopla	sm of	majo	r saliv	ary g	lands														
Males	0	0	0	0	1	0	0	2	2	1	2	1	0	2	1	4	0	1	17			
Rate	0.0	0.0	0.0	0.0	1.3	0.0	0.0	3.2	3.4	1.7	4.5	3.2	0.0	10.9	6.9	45.9	0.0	41.3		2.2	2.1 (1.3 - 3.4)	569
Females	0	0	0	0	1	0	2	0	0	0	0	0	0	0	0	3	0	1	7			
Rate	0.0	0.0	0.0	0.0	1.4	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.9	0.0	17.1		0.9	0.6 (0.3 - 1.3)	4414
Persons	0	0	0	0	2	0	2	2	2	1	2	1	0	2	1	7	0	2	24			
Rate	0.0	0.0	0.0	0.0	1.3	0.0	1.6	1.6	1.7	0.8	2.3	1.7	0.0	5.3	3.1	32.9	0.0	24.2		1.6	1.3 (0.9 - 1.9)	1031
143	Malign	ant 1	neopla	sm of	gum																	
Males	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0		0.1	0.2 (0.0 - 1.3)	4512
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				
Persons	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0		0.1	0.1 (0.0 - 0.6)	8872
144	Malign	ant 1	neopla	sm of	floor	of mo	outh															
Males	0	0	0	0	0	0	0	0	1	0	2	2	3	1	0	0	0	0	9			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	4.5	6.5	13.3	5.5	0.0	0.0	0.0	0.0		1.2	1.3 (0.7 - 2.5)	636
Females	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	2			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0		0.3	0.3 (0.1 - 1.0)	2951
Persons	0	0	0	0	0	0	0	1	1	0	2	2	3	2	0	0	0	0	11			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.0	2.3	3.3	6.8	5.3	0.0	0.0	0.0	0.0		0.7	0.8 (0.4 - 1.4)	1034

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
145	Malign	ant r	neopla	sm of	other	and t	unspe	cified _]	parts	of mou	ıth											
Males	0	0	0	0	0	0	0	0	1	0	0	1	2	0	0	1	0	0	5			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	3.2	8.9	0.0	0.0	11.5	0.0	0.0		0.7	0.7 (0.3 - 1.7)	1449
Females	0	0	0	0	0	1	0	0	1	1	0	1	0	0	4	0	0	0	8			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	1.6	1.7	0.0	3.4	0.0	0.0	22.6	0.0	0.0	0.0		1.0	0.9 (0.5 - 1.8)	649
Persons	0	0	0	0	0	1	0	0	2	1	0	2	2	0	4	1	0	0	13			
Rate	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.7	0.8	0.0	3.3	4.5	0.0	12.4	4.7	0.0	0.0		0.9	0.8 (0.5 - 1.4)	851
146	Malign	ant r	1eopl a	sm of	oropl	naryn	X															
Males	0	0	0	0	0	0	0	0	2	0	3	2	1	0	0	0	0	0	8			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	6.8	6.5	4.4	0.0	0.0	0.0	0.0	0.0		1.0	1.0 (0.5 - 2.0)	950
Females	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	3			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	5.2	5.6	0.0	0.0	0.0		0.4	0.4 (0.1 - 1.2)	1518
Persons	0	0	0	0	0	0	0	0	2	0	4	2	1	1	1	0	0	0	11			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	4.6	3.3	2.3	2.7	3.1	0.0	0.0	0.0		0.7	0.7 (0.4 - 1.3)	1136
147	Malign	ant r	ieopla	sm of	f nasop	hary	nx															
Males	0	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	4			
Rate	0.0	1.8	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	41.3		0.5	0.7 (0.3 - 1.9)	2513
Females	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	2			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.3	0.2 (0.1 - 0.9)	5024
Persons	0	1	1	0	0	0	0	0	1	0	1	0	1	0	0	0	0	1	6			
Rate	0.0	0.9	0.9	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.1	0.0	2.3	0.0	0.0	0.0	0.0	12.1		0.4	0.4 (0.2 - 1.0)	3310

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
148	Malign	ant 1	neopla	asm of	hypo	phary	nx															
Males	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	4			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	5.5	13.8	0.0	0.0	0.0		0.5	0.6 (0.2 - 1.6)	845
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				
Persons	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	4			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	2.7	6.2	0.0	0.0	0.0		0.3	0.3 (0.1 - 0.8)	1799
149	Malign	ant 1	neopla	asm of	other	and i	ll-defi	ned si	tes wi	thin th	ne lip,	oral c	avity,	and p	haryn	K						
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	2			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	41.3		0.3	0.4 (0.1 - 1.5)	3655
Females	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	0.0		0.1	0.2 (0.0 - 1.3)	4361
Persons	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	3			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	2.7	0.0	0.0	0.0	12.1		0.2	0.2 (0.1 - 0.7)	4066
150	Malign	ant 1	neopla	sm of	oesop	hagu	S															
Males	0	0	0	0	0	0	0	0	1	4	2	4	2	6	8	3	4	0	34			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	6.8	4.5	13.0	8.9	32.8	55.1	34.4	89.9	0.0		4.4	4.5 (3.2 - 6.3)	163
Females	0	0	0	0	0	0	0	0	0	0	0	0	2	3	5	5	2	4	21			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.2	15.6	28.2	39.9	25.9	68.5		2.8	2.3 (1.5 - 3.5)	378
Persons	0	0	0	0	0	0	0	0	1	4	2	4	4	9	13	8	6	4	55			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	3.4	2.3	6.7	9.0	24.0	40.3	37.7	49.3	48.4		3.6	3.4 (2.5 - 4.3)	232

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
151	Malign	ant 1	ieopla	sm of	stoma	ach																
Males	0	0	0	0	0	0	0	4	1	7	5	5	11	8	10	1	8	5	65			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	1.7	11.9	11.3	16.2	48.8	43.8	68.9	11.5	179.9	206.4		8.5	9.1 (6.9 - 11.3)	96
Females	0	0	0	0	0	1	0	1	1	0	2	3	3	9	5	5	5	7	42			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	0.0	1.6	1.6	0.0	4.7	10.3	13.8	46.7	28.2	39.9	64.7	119.8		5.5	4.8 (3.5 - 6.5)	185
Persons	0	0	0	0	0	1	0	5	2	7	7	8	14	17	15	6	13	12	107			
Rate	0.0	0.0	0.0	0.0	0.0	0.8	0.0	4.0	1.7	5.9	8.0	13.3	31.6	45.3	46.5	28.2	106.7	145.2		7.0	6.8 (5.5 - 8.1)	128
152	Malign	ant 1	1eopl a	sm of	small	intes	tine, i	ncludi	ng du	odenu	m											
Males	0	0	0	0	0	0	0	0	0	2	0	1	1	1	1	0	0	1	7			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	3.2	4.4	5.5	6.9	0.0	0.0	41.3		0.9	1.0 (0.5 - 2.1)	854
Females	0	0	0	1	0	0	0	0	0	1	0	0	3	0	1	0	0	2	8			
Rate	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	13.8	0.0	5.6	0.0	0.0	34.2		1.0	1.1 (0.5 - 2.2)	879
Persons	0	0	0	1	0	0	0	0	0	3	0	1	4	1	2	0	0	3	15			
Rate	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	2.5	0.0	1.7	9.0	2.7	6.2	0.0	0.0	36.3		1.0	1.0 (0.6 - 1.7)	873
153	Malign	ant 1	1eopl a	sm of	colon	l																
Males	0	0	0	0	0	1	0	4	11	11	18	36	38	25	34	21	12	9	220			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	0.0	6.5	18.6	18.7	40.5	116.8	168.5	136.8	234.3	241.1	269.8	371.4		28.7	30.6 (26.6 - 34.6)	27
Females	0	0	0	0	0	1	2	4	4	11	19	21	17	21	30	18	19	12	179			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	3.2	6.3	6.6	18.6	44.5	71.8	78.0	109.1	169.2	143.6	245.7	205.4		23.5	20.8 (17.7 - 23.8)	40
Persons	0	0	0	0	0	2	2	8	15	22	37	57	55	46	64	39	31	21	399			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	1.6	6.4	12.5	18.7	42.5	94.9	124.0	122.6	198.5	183.6	254.5	254.1		26.1	25.4 (22.9 - 27.9)	33

Age Yrs 5-9 10-14 15-19 20-24 25-29 30-34 65-69 75-79 85+ Total CR ASR 95% CI Life Risk (1 in)154 Malignant neoplasm of rectum, rectosigmoid junction, and anus Males 0 0 0 0 2 0 5 10 11 20 15 17 18 14 0 2 116 82.5 0.0 0.0 0.0 0.0 2.6 1.5 1.6 0.0 8.5 17.0 24.8 64.9 66.5 93.0 124.0 160.7 0.0 **15.1 15.7** (12.9 - 18.6) Rate 50 0 0 0 0 5 12 81 Females 13 11 Rate 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.6 4.9 11.9 11.7 44.4 22.9 36.4 45.1 87.7 103.5 205.4 10.6 **8.9** (7.0 - 10.8) 111 2 Persons 0 0 0 0 2 17 16 33 20 24 26 25 14 197 Rate 0.0 0.0 0.0 0.0 1.3 0.8 1.6 0.8 6.7 14.4 18.4 54.9 45.1 64.0 80.6 117.7 65.7 169.4 **12.9 12.4** (10.6 - 14.1) 70 Malignant neoplasm of liver and intrahepatic bile ducts 155 18 Males 0 0 0 0 0 0 0 0 3 0 0 2 5 2 0 5.1 27.4 22.5 0.0 0.0 0.0 0.0 1.7 0.0 0.0 8.9 13.8 45.9 0.0 2.3 353 Rate 0.00.0 0.0 0.0 **2.4** (1.5 - 3.9) 7 0 0 0 0 0 1 0 0 0 Females 0.0 0.0 0.0 0.0 1.7 0.0 0.0 5.2 0.0 8.0 12.9 17.1 0.9 1890 Rate 0.0 0.0 0.0 0.0 0.0 **0.9** (0.4 - 2.0) Persons 0 0 0 0 0 0 4 0 0 2 2 5 25 6 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 3.4 0.0 0.0 4.5 16.0 6.2 23.5 16.4 12.1 Rate **1.6** (1.1 - 2.4) 611 Malignant neoplasm of gall bladder and extrahepatic bile ducts **156** 13 0 0 0 0 0 0 0 0 0 3 5 0 Males 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 4.4 5.5 20.7 23.0 112.4 0.0 1.7 Rate **1.6** (1.0 - 2.8) 620 Females 0 0 0 0 0 0 0 0 0 0 2 3 3 2 14 0.0 9.2 5.2 23.9 38.8 34.2 Rate 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.7 0.0 5.6 1.8 **1.4** (0.9 - 2.4) 857 2 2 27 0 0 0 0 0 0 0 2 1 0 3 5 8 Persons Rate 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.8 0.0 0.0 6.8 5.3 12.4 23.5 65.7 24.2 1.8 **1.5** (1.0 - 2.2) 741

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
157	Malign	ant 1	neopla	sm of	pancı	reas																
Males	0	0	0	0	0	0	1	0	1	4	3	3	7	3	10	5	3	5	45			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	1.7	6.8	6.8	9.7	31.0	16.4	68.9	57.4	67.5	206.4		5.9	6.4 (4.8 - 8.6)	140
Females	0	0	0	0	0	0	0	0	1	2	1	3	4	5	8	6	9	4	43			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	3.4	2.3	10.3	18.3	26.0	45.1	47.9	116.4	68.5		5.6	4.6 (3.4 - 6.3)	187
Persons	0	0	0	0	0	0	1	0	2	6	4	6	11	8	18	11	12	9	88			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.7	5.1	4.6	10.0	24.8	21.3	55.8	51.8	98.5	108.9		5.8	5.4 (4.3 - 6.5)	162
158	Malign	ant 1	1eopl a	sm of	retro	perito	neum	and p	eritor	neum												
Males	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.1	0.1 (0.0 - 0.8)	8884
Females	0	0	0	1	0	0	0	1	0	1	0	0	0	0	1	0	0	0	4			
Rate	0.0	0.0	0.0	1.7	0.0	0.0	0.0	1.6	0.0	1.7	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0		0.5	0.5 (0.2 - 1.2)	1889
Persons	0	0	0	1	0	0	0	1	0	1	1	0	0	0	1	0	0	0	5			
Rate	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.8	0.0	0.8	1.1	0.0	0.0	0.0	3.1	0.0	0.0	0.0		0.3	0.3 (0.1 - 0.7)	2979
159	Malign	ant 1	neopla	sm of	other	and i	ll-defi	ned si	tes wi	thin th	ne dige	estive	organ	s and j	perito	neum						
Males	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	0	4			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	3.2	0.0	0.0	6.9	11.5	0.0	0.0		0.5	0.5 (0.2 - 1.3)	1615
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.9	0.0		0.1	0.1 (0.0 - 0.5)	
Persons	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1	1	0	5			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.7	0.0	0.0	3.1	4.7	8.2	0.0		0.3	0.3 (0.1 - 0.7)	3382

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
160	Malign	ant 1	neopla	sm of	nasal	cavit	ies, mi	iddle e	ar, ar	nd acce	essory	sinus	es									
Males	0	0	0	0	0	0	0	2	1	1	0	0	0	0	0	0	0	0	4			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	1.7	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.5	0.4 (0.1 - 1.1)	3019
Females	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	0	4			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	2.3	3.4	0.0	0.0	0.0	8.0	0.0	0.0		0.5	0.4 (0.2 - 1.2)	2684
Persons	0	0	0	0	0	0	0	2	1	2	1	1	0	0	0	1	0	0	8			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.8	1.7	1.1	1.7	0.0	0.0	0.0	4.7	0.0	0.0		0.5	0.4 (0.2 - 0.8)	2882
161	Malign	ant 1	neopla	sm of	laryn	X																
Males	0	0	0	0	0	0	0	0	0	1	5	4	3	4	3	3	2	1	26			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	11.3	13.0	13.3	21.9	20.7	34.4	45.0	41.3		3.4	3.6 (2.4 - 5.2)	245
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	4			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	5.6	8.0	12.9	0.0		0.5	0.4 (0.2 - 1.1)	1847
Persons	0	0	0	0	0	0	0	0	0	1	5	4	3	5	4	4	3	1	30			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	5.7	6.7	6.8	13.3	12.4	18.8	24.6	12.1		2.0	1.9 (1.3 - 2.7)	438
162	Malign	ant 1	neopla	sm of	f trach	ea, br	onchu	ıs, and	l lung													
Males	0	0	0	0	0	0	1	3	5	11	6	19	27	29	37	35	18	5	196			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	1.6	4.8	8.5	18.7	13.5	61.6	119.7	158.7	255.0	401.8	404.8	206.4		25.6	26.9 (23.1 - 30.6	5) 32
Females	0	0	0	0	0	0	2	1	6	7	10	12	19	24	27	16	11	12	147			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	3.2	1.6	9.8	11.9	23.4	41.0	87.1	124.6	152.3	127.6	142.2	205.4		19.3	17.7 (14.8 - 20.5	5) 44
Persons	0	0	0	0	0	0	3	4	11	18	16	31	46	53	64	51	29	17	343			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	2.4	3.2	9.2	15.3	18.4	51.6	103.7	141.2	198.5	240.0	238.1	205.7		22.4	21.8 (19.5 - 24.1	1) 37

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
163	Malign	ant 1	neopla	sm of	f pleur	a																
Males	0	0	0	0	0	0	0	1	0	1	0	1	2	2	1	0	1	1	10			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	1.7	0.0	3.2	8.9	10.9	6.9	0.0	22.5	41.3		1.3	1.5 (0.8 - 2.7)	602
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	3			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	5.6	0.0	0.0	17.1		0.4	0.4 (0.1 - 1.1)	1847
Persons	0	0	0	0	0	0	0	1	0	1	0	1	2	3	2	0	1	2	13			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.8	0.0	1.7	4.5	8.0	6.2	0.0	8.2	24.2		0.9	0.9 (0.5 - 1.5)	909
164	Malign	ant 1	neopla	sm of	thym	us, he	art, a	nd me	diastii	num												
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.5	0.0		0.1	0.1 (0.0 - 0.8)	
Females	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.1	0.1 (0.0 - 0.7)	12632
Persons	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	2			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.2	0.0		0.1	0.1 (0.0 - 0.4)	25394
170	Malign	ant 1	neopla	sm of	bone	and a	rticul	ar car	tilage													
Males	0	1	0	0	1	1	0	0	0	0	3	0	1	1	0	0	0	0	8			
Rate	0.0	1.8	0.0	0.0	1.3	1.5	0.0	0.0	0.0	0.0	6.8	0.0	4.4	5.5	0.0	0.0	0.0	0.0		1.0	1.1 (0.5 - 2.2)	943
Females	0	0	1	3	1	0	0	0	0	0	0	0	0	0	0	1	0	0	6			
Rate	0.0	0.0	1.9	5.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.0	0.0	0.0		0.8	0.8 (0.4 - 1.8)	2426
Persons	0	1	1	3	2	1	0	0	0	0	3	0	1	1	0	1	0	0	14			
Rate	0.0	0.9	0.9	2.5	1.3	0.8	0.0	0.0	0.0	0.0	3.4	0.0	2.3	2.7	0.0	4.7	0.0	0.0		0.9	0.9 (0.6 - 1.6)	1360

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
171	Malign	ant r	neopla	sm of	conne	ective	and o	ther s	oft tis	sue												
Males	1	0	0	0	2	0	0	0	1	0	1	3	2	1	0	1	1	0	13			
Rate	1.8	0.0	0.0	0.0	2.6	0.0	0.0	0.0	1.7	0.0	2.3	9.7	8.9	5.5	0.0	11.5	22.5	0.0		1.7	1.8 (1.0 - 3.0)	619
Females	0	0	0	0	0	1	0	0	2	0	3	0	1	2	3	2	1	0	15			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	3.3	0.0	7.0	0.0	4.6	10.4	16.9	16.0	12.9	0.0		2.0	1.7 (1.0 - 2.9)	458
Persons	1	0	0	0	2	1	0	0	3	0	4	3	3	3	3	3	2	0	28			
Rate	0.9	0.0	0.0	0.0	1.3	0.8	0.0	0.0	2.5	0.0	4.6	5.0	6.8	8.0	9.3	14.1	16.4	0.0		1.8	1.8 (1.2 - 2.6)	512
172	Malign	ant r	nelan	oma o	f skin																	
Males	0	0	2	0	4	8	10	13	30	32	40	27	21	35	28	13	8	3	274			
Rate	0.0	0.0	3.5	0.0	5.1	12.1	15.7	21.0	50.8	54.4	90.1	87.6	93.1	191.6	192.9	149.2	179.9	123.8		35.8	34.6 (30.5 - 38.6	6) 25
Females	0	0	0	1	11	10	11	17	21	22	24	29	16	18	10	10	6	7	213			
Rate	0.0	0.0	0.0	1.7	15.0	15.4	17.4	26.9	34.4	37.3	56.2	99.1	73.4	93.5	56.4	79.8	77.6	119.8		27.9	25.0 (21.6 - 28.3	3) 38
Persons	0	0	2	1	15	18	21	30	51	54	64	56	37	53	38	23	14	10	487			
Rate	0.0	0.0	1.8	0.8	9.9	13.8	16.5	24.0	42.5	45.8	73.5	93.2	83.4	141.2	117.9	108.3	114.9	121.0		31.9	29.5 (26.8 - 32.	1) 31
174	Malign	ant r	neopla	sm of	femal	le bre	ast															
Females	0	0	0	0	0	4	19	35	74	116	120	84	66	61	65	37	25	17	723			
Rate	0.0	0.0	0.0	0.0	0.0	6.2	30.1	55.4	121.2	196.5	281.2	287.1	302.7	316.8	366.6	295.1	323.3	291.0		94.8	85.2 (79.0 - 91.4	4) 11
175	Malign	ant r		asm of	male	breas	t															
Males	0	0	0	0	0	0	0	1	0	0	1	0	2	1	0	2	0	0	7			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	2.3	0.0	8.9	5.5	0.0	23.0	0.0	0.0		0.9	1.0 (0.5 - 2.0)	1099

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
179	Malign	ant 1	neopla	sm of	uteru	s, par	t															
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.0	0.0	17.1		0.3	0.2 (0.0 - 0.8)	3547
180	Malign	ant 1	neopla	sm of	cervi	x uter	i															
Females	0	0	0	0	0	5	4	9	12	7	6	7	2	1	6	0	5	1	65			
Rate	0.0	0.0	0.0	0.0	0.0	7.7	6.3	14.3	19.7	11.9	14.1	23.9	9.2	5.2	33.8	0.0	64.7	17.1		8.5	7.0 (5.3 - 8.7)	137
182	Malign	ant r	neopla	sm of	body	of ute	erus															
Females	0	0	0	0	0	2	1	1	3	4	9	12	12	16	10	10	3	0	83			
Rate	0.0	0.0	0.0	0.0	0.0	3.1	1.6	1.6	4.9	6.8	21.1	41.0	55.0	83.1	56.4	79.8	38.8	0.0		10.9	10.6 (8.4 - 12.9)	73
183	Malign	ant r	neopla	sm of	ovary	and	other	uterin	e adn	exa												
Females	0	0	0	0	1	1	1	1	4	15	11	8	6	8	8	2	1	0	67			
Rate	0.0	0.0	0.0	0.0	1.4	1.5	1.6	1.6	6.6	25.4	25.8	27.3	27.5	41.5	45.1	16.0	12.9	0.0		8.8	8.2 (6.2 - 10.2)	98
184	Malign	ant 1	neopla	sm of	other	and ı	ınspec	cified f	emale	e genit	al org	ans										
Females	0	0	0	0	0	0	0	0	0	3	0	1	0	2	3	1	0	3	13			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	3.4	0.0	10.4	16.9	8.0	0.0	51.4		1.7	1.4 (0.8 - 2.5)	559

Age Yrs 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Total CR ASR 95% CI Life Risk

185	Malign	ant n	eopla	sm of	prosta	ite																
Males	0	0	0	0	0	1	0	0	1	8	37	85	107	181	176	112	64	32	804			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	1.7	13.6	83.3	275.8	474.4	990.6	1212.8	1285.7	1439.2	1320.7		104.9	115.8 (107.8 –123.	8) 7
186	Malign	ant n	eopla	sm of	testis																	
Males	1	0	0	1	9	6	13	10	9	6	2	3	0	0	0	0	0	0	60			
Rate	1.8	0.0	0.0	1.6	11.5	9.1	20.4	16.2	15.2	10.2	4.5	9.7	0.0	0.0	0.0	0.0	0.0	0.0		7.8	6.3 (4.7 - 7.9)	200
187	Malign	ant n	eopla	sm of	penis	and o	ther n	nale go	enital	organ	s											
Males	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	1	4			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.7	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	41.3		0.5	0.5 (0.2 - 1.4)	3052
188	Malign	ant n	eopla	sm of	bladd	er																
Males	0	0	0	1	0	0	0	0	1	3	4	2	7	21	15	10	8	3	75			
Rate	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	1.7	5.1	9.0	6.5	31.0	114.9	103.4	114.8	179.9	123.8		9.8	10.7 (8.3 - 13.1)	74
	0	0	0	0	0	0	0	1	0	1	0	2	2	5	1	2	2	2	18			
Females											0.0	- 0	0.2	26.0	5 6	1.0	25.0	242				202
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	1.7	0.0	6.8	9.2	26.0	5.6	16.0	25.9	34.2		2.4	2.2 (1.4 - 3.5)	393
Females Rate Persons	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6 1	0.0	1.7	0.0	6.8	9.2	26.0	16	12	10	34.2	93	2.4	2.2 (1.4 - 3.5)	393

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
189	Malign	ant 1	neopla	asm of	kidne	ey and	l other	and ı	ınspeo	cified 1	urinar	y orga	ans									
Males	0	0	1	1	0	0	1	2	6	4	10	8	8	6	9	8	6	0	70			
Rate	0.0	0.0	1.8	1.6	0.0	0.0	1.6	3.2	10.2	6.8	22.5	26.0	35.5	32.8	62.0	91.8	134.9	0.0		9.1	9.0 (6.9 - 11.1)	99
Females	1	0	0	0	0	0	0	1	0	2	4	3	3	4	7	7	5	3	40			
Rate	1.8	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	3.4	9.4	10.3	13.8	20.8	39.5	55.8	64.7	51.4		5.2	4.5 (3.3 - 6.1)	200
Persons	1	0	1	1	0	0	1	3	6	6	14	11	11	10	16	15	11	3	110			
Rate	0.9	0.0	0.9	0.8	0.0	0.0	0.8	2.4	5.0	5.1	16.1	18.3	24.8	26.6	49.6	70.6	90.3	36.3		7.2	6.7 (5.5 – 8.0)	133
190	Malign	ant 1	neopla	asm of	eye																	
Males	2	0	0	0	0	2	0	0	1	0	0	1	0	1	2	0	1	0	10			
Rate	3.6	0.0	0.0	0.0	0.0	3.0	0.0	0.0	1.7	0.0	0.0	3.2	0.0	5.5	13.8	0.0	22.5	0.0		1.3	1.5 (0.8 - 2.7)	650
Females	0	0	0	0	0	0	1	0	0	0	1	2	0	0	0	0	1	1	6			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	2.3	6.8	0.0	0.0	0.0	0.0	12.9	17.1		0.8	0.6 (0.3 - 1.4)	1859
Persons	2	0	0	0	0	2	1	0	1	0	1	3	0	1	2	0	2	1	16			
Rate	1.8	0.0	0.0	0.0	0.0	1.5	0.8	0.0	0.8	0.0	1.1	5.0	0.0	2.7	6.2	0.0	16.4	12.1		1.0	1.0 (0.6 - 1.7)	1002
191	Malign	ant 1	1eopl a	asm of	brain	l																
Males	0	1	1	2	3	2	3	3	4	2	6	5	4	7	5	4	2	1	55			
Rate	0.0	1.8	1.8	3.2	3.8	3.0	4.7	4.8	6.8	3.4	13.5	16.2	17.7	38.3	34.5	45.9	45.0	41.3		7.2	7.1 (5.2 - 9.0)	131
Females	1	1	1	0	1	1	2	2	1	2	3	7	0	2	4	1	1	0	30			
Rate	1.8	1.9	1.9	0.0	1.4	1.5	3.2	3.2	1.6	3.4	7.0	23.9	0.0	10.4	22.6	8.0	12.9	0.0		3.9	3.7 (2.6 - 5.3)	239
Persons	1	2	2	2	4	3	5	5	5	4	9	12	4	9	9	5	3	1	85			
Rate	0.9	1.8	1.8	1.6	2.6	2.3	3.9	4.0	4.2	3.4	10.3	20.0	9.0	24.0	27.9	23.5	24.6	12.1		5.6	5.3 (4.2 - 6.4)	170

Age Yrs 5-9 10-14 15-19 20-24 25-29 30-34 65-69 70-74 75-79 80-84 85+ Total CR ASR 95% CI Life Risk (1 in)192 Malignant neoplasm of other and unspecified parts of nervous system Males 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Rate 0 0 0 0 0 0 0 0 0 3 Females 1 0 Rate 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 12.9 0.0 0.4 **0.3** (0.1 - 1.0) 5637 3 Persons 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 Rate 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 8.2 0.0 0.2 **0.2** (0.1 - 0.5) **11406** Malignant neoplasm of thyroid gland 193 13 Males 0 0 0 0 2 0 0 1 2 0 0 0 3.1 10.9 0.0 0.0 0.0 0.0 3.8 1.5 1.7 0.0 0.0 3.2 4.4 0.0 0.0 Rate 1.6 6.9 0.0 **1.6** (0.9 - 2.7) 536 0 2 11 3 7 2 0 0 3 0 41 Females 6 0.0 1.9 1.7 2.7 9.3 3.2 17.4 4.9 11.9 4.7 3.4 0.0 5.2 0.0 23.9 0.0 17.1 303 Rate 0.0 **4.4** (3.2 - 5.9) 0 0 4 12 1 3 3 0 54 Persons 0.0 0.0 0.9 0.8 3.3 5.4 3.2 9.6 3.3 5.9 2.3 3.3 2.3 8.0 3.1 14.1 0.0 12.1 3.5 **3.0** (2.2 - 3.8) 390 Rate Malignant neoplasm of endocrine glands and related structures 194 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Males 0 3.6 0.0 0.0 0.0 3.8 1.5 3.1 1.7 0.0 0.0 3.2 4.4 10.9 0.0 0.0 0.0 Rate 1.6 6.9 0.3 **0.4** (0.1 – 1.7) **5628** 2 Females 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 Rate 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 00 0.0 **0.3** (0.1 - 1.1) 6213 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 4 Persons Rate 1.8 0.0 0.0 0.8 0.0 0.8 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 8.2 0.0 0.3 **0.4** (0.1 - 0.9) 5893

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
195	Malign	ant 1	neopla	sm of	other	and i	ill-defi	ned si	tes													
Males	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0		0.1	0.2 (0.0 - 1.3)	4512
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				
Persons	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0		0.1	0.1 (0.0 - 0.6)	8872
199	Malign	ant 1	neopla	asm w	ithout	speci	ficatio	n of si	ite													
Males	0	0	0	0	0	1	1	0	4	6	5	12	14	14	13	14	5	5	94			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	1.6	0.0	6.8	10.2	11.3	38.9	62.1	76.6	89.6	160.7	112.4	206.4		12.3	13.1 (10.5 - 15.8	67
Females	0	0	0	0	0	2	1	0	3	2	7	5	2	6	7	10	14	13	72			
Rate	0.0	0.0	0.0	0.0	0.0	3.1	1.6	0.0	4.9	3.4	16.4	17.1	9.2	31.2	39.5	79.8	181.0	222.6		9.4	7.3 (5.6 - 8.9)	159
Persons	0	0	0	0	0	3	2	0	7	8	12	17	16	20	20	24	19	18	166			
Rate	0.0	0.0	0.0	0.0	0.0	2.3	1.6	0.0	5.8	6.8	13.8	28.3	36.1	53.3	62.0	113.0	156.0	217.8		10.9	10.1 (8.6 - 11.7)	96
200	Lymph	osar	coma	and r	eticul	osarco	oma															
Males	0	1	0	0	0	0	0	4	2	2	4	2	3	3	6	9	4	1	41			
Rate	0.0	1.8	0.0	0.0	0.0	0.0	0.0	6.5	3.4	3.4	9.0	6.5	13.3	16.4	41.3	103.3	89.9	41.3		5.4	5.2 (3.8 - 7.1)	197
Females	0	0	0	0	0	0	0	1	1	1	7	8	3	6	12	5	5	3	52			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.6	1.7	16.4	27.3	13.8	31.2	67.7	39.9	64.7	51.4		6.8	6.0 (4.4 - 7.7)	125
Persons	0	1	0	0	0	0	0	5	3	3	11	10	6	9	18	14	9	4	93			
Rate	0.0	0.9	0.0	0.0	0.0	0.0	0.0	4.0	2.5	2.5	12.6	16.6	13.5	24.0	55.8	65.9	73.9	48.4		6.1	5.6 (4.4 - 6.7)	151

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk (1 in)
201	Hodgki	in's d	liseas	e																		
Males	0	0	2	0	2	2	0	4	2	1	0	0	0	1	0	0	0	0	14			
Rate	0.0	0.0	3.5	0.0	2.6	3.0	0.0	6.5	3.4	1.7	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0		1.8	1.6 (1.0 - 2.7)	765
Females	0	0	3	3	4	3	1	2	0	2	1	0	0	1	1	0	0	0	21			
Rate	0.0	0.0	5.6	5.0	5.5	4.6	1.6	3.2	0.0	3.4	2.3	0.0	0.0	5.2	5.6	0.0	0.0	0.0		2.8	2.6 (1.7 - 4.0)	477
Persons	0	0	5	3	6	5	1	6	2	3	1	0	0	2	1	0	0	0	35			
Rate	0.0	0.0	4.5	2.5	4.0	3.8	0.8	4.8	1.7	2.5	1.1	0.0	0.0	5.3	3.1	0.0	0.0	0.0		2.3	2.1 (1.5 - 3.0)	586
202	Other 1	nalig	gnant	neopl	asms (of lym	phoid	and h	istioc	ytic tis	ssue											
Males	0	0	2	1	0	0	1	0	4	12	5	5	7	4	12	1	5	2	61			
Rate	0.0	0.0	3.5	1.6	0.0	0.0	1.6	0.0	6.8	20.4	11.3	16.2	31.0	21.9	82.7	11.5	112.4	82.5		8.0	8.0 (6.0 - 10.1	102
Females	0	0	0	0	0	1	2	4	2	3	2	5	5	9	3	5	4	2	47			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	3.2	6.3	3.3	5.1	4.7	17.1	22.9	46.7	16.9	39.9	51.7	34.2		6.2	5.6 (4.2 - 7.5)	157
Persons	0	0	2	1	0	1	3	4	6	15	7	10	12	13	15	6	9	4	108			
Rate	0.0	0.0	1.8	0.8	0.0	0.8	2.4	3.2	5.0	12.7	8.0	16.6	27.1	34.6	46.5	28.2	73.9	48.4		7.1	6.7 (5.4 - 8.0)	126
203	Multip	le my	yelom	a and	immu	nopro	olifera	tive n	eoplas	sms												
Males	0	0	0	0	0	1	0	0	1	0	3	3	4	5	5	3	3	3	31			
Rate	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	1.7	0.0	6.8	9.7	17.7	27.4	34.5	34.4	67.5	123.8		4.0	4.5 (3.1 - 6.4)	202
Females	0	0	0	0	0	0	0	0	0	0	2	1	0	1	4	4	1	2	15			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	3.4	0.0	5.2	22.6	31.9	12.9	34.2		2.0	1.5 (0.9 - 2.5)	558
Persons	0	0	0	0	0	1	0	0	1	0	5	4	4	6	9	7	4	5	46			
Rate	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.8	0.0	5.7	6.7	9.0	16.0	27.9	32.9	32.8	60.5		3.0	2.9 (2.1 – 3.8)	299

Age Yrs 5-9 10-14 15-19 20-24 25-29 30-34 65-69 75-79 85+ Total CR ASR 95% CI (1 in)Lymphoid leukaemia 204 Males 0 0 0 2 0 2 2 3 0 0 21 3.2 Rate 3.6 1.8 0.0 1.3 0.0 1.6 0.0 0.0 3.4 0.0 13.0 8.9 5.5 13.8 34.4 0.0 0.0 2.7 **2.9** (1.9 - 4.5) 359 3 26 5 0 0 Females 2 0 0 1 9.2 3.7 0.0 0.0 23.9 Rate 1.7 0.0 0.0 0.0 1.6 1.6 13.7 4.6 5.2 11.3 0.0 17.1 **3.7** (2.5 - 5.5) 323 7 3 0 3 2 8 3 2 0 47 Persons 0 6 Rate 6.3 2.7 0.0 2.5 0.7 0.0 0.8 0.8 0.8 1.7 13.3 6.8 5.3 12.4 28.2 0.0 12.1 **3.3** (2.5 - 4.4) 341 4.6 3.1 205 Myeloid leukaemia Males 2 0 0 2 2 2 5 5 2 32 3.2 1.7 8.9 41.3 3.6 0.0 0.0 1.3 3.0 3.1 1.7 6.5 5.5 34.5 57.4 45.0 4.2 254 Rate 1.6 **4.2** (3.0 - 6.0) 0 2 2 3 2 28 0 0 1 Females Rate 1.8 0.0 1.9 0.0 1.4 1.5 0.0 1.6 1.6 3.4 4.7 6.8 4.6 15.6 39.5 16.0 12.9 34.2 3.7 **3.4** (2.3 - 4.9) 238 2 2 3 3 Persons 3 0 2 4 4 3 12 3 60 2.7 32.9 0.0 0.9 1.6 1.3 2.3 1.7 2.5 6.7 6.8 10.7 37.2 24.6 36.3 **3.8** (2.8 - 4.7) 244 Rate 1.6 1.6 4.6 Monocytic leukaemia 206 Males 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Rate 0.0 0.0 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Females 0 Rate 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 **0.1** (0.0 - 0.8) 8536 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Persons

Source: ACT Cancer Registry

0.1 (0.0 - 0.4) **17420**

Rate

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Cancer Incidence in the ACT by age, sex and site 1994-1998

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI	Life Risk
																						(1 in)
208	Leukae	mia	of uns	specifi	ied cel	l type																
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0		0.1	0.2 (0.0 - 1.2)	3655
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.9	17.1		0.3	0.2 (0.0 - 0.6)	
Persons	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	3			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	8.2	12.1		0.2	0.2 (0.1 - 0.6)	7506

TABLES

CANCER MORTALITY IN THE ACT

by age, sex and site

1994 – 1997

Age Yrs 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Total CR ASR 95% CI

Males	4	3	2	3	6	5	3	12	30	42	40	75	81	116	146	105	85	66	824			
Rate	8.8	6.6	4.4	6.0	9.4	9.5	5.8	24.2	63.3	88.9	117.2	311.6	456.6	800.1	1268.7	1591.4	2473.8	3556.0		134.5	147.0	(137.1-157.1
Females	2	0	1	1	0	8	5	12	26	50	61	61	55	77	100	83	96	65	703			
Rate	4.6	0.0	2.3	2.1	0.0	15.6	9.8	23.9	53.4	106.7	185.6	268.1	323.0	503.0	708.5	859.4	1598.1	1459.0		115.6	99.9	(92.5 –107.3
Persons	6	3	3	4	6	13	8	24	56	92	101	136	137	193	246	188	181	131	1527			
Rate	6.7	3.4	3.4	4.1	4.9	12.5	7.8	24.0	58.3	97.8	150.7	290.4	394.1	647.5	960.1	1156.5	1916.8	2075.7		125.1	119.6	(113.6-125.5
140 I	Malign	ant n	eopla	sm of	lip																	
Males	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.2	0.1	(0.0 - 0.9)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				
Persons	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.1	0.1	(0.0 - 0.4)
141 I	Malign	ant n	eopla	sm of	tongu	e																
Males	0	0	0	0	0	0	0	0	0	0	0	3	0	0	2	0	0	0	5			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.5	0.0	0.0	17.4	0.0	0.0	0.0		0.8	0.8	(0.4 - 2.0)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				
Persons	0	0	0	0	0	0	0	0	0	0	0	3	0	0	2	0	0	0	5			
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	7.8	0.0	0.0	0.0		0.4	0.4	(0.2 - 1.0)

Age Yr	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ T	otal	CR	ASR 95% CI
142	Malign	ant 1	neopla	sm of	i majo	r saliv	vary g	lands													
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.7	15.2	0.0	0.0		0.3	0.3 (0.1 - 1.3)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0		0.2	0.1 (0.0 - 1.0)
Persons	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	3		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.8	6.2	0.0	0.0		0.2	0.2 (0.1 - 0.7)
144	Malign	ant 1	neopla	sm of	floor	of mo	uth														
Males	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0		0.2	0.2 (0.0 - 1.2)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Persons	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0		0.1	0.1 (0.0 - 0.6)
145	Malign	ant 1	neopla	sm of	other	and i	unspec	cified 1	parts	of mou	ıth										
Males	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0		0.2	0.2 (0.0 - 1.6)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	7.1	0.0	0.0	0.0		0.3	0.3 (0.1 - 1.4)
Persons	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	3		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	3.4	3.9	0.0	0.0	0.0		0.2	0.3 (0.1 - 0.9)

Age Yrs	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ T	otal	CR	ASR 95% CI
146	Malign	ant 1	neopla	sm of	f orop	haryn	X														
Males	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.2	0.1 (0.0 - 0.9)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	3		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	14.2	0.0	0.0	0.0		0.5	0.5 (0.2 - 1.5)
Persons	0	0	0	0	0	0	0	0	1	0	0	0	0	1	2	0	0	0	4		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	3.4	7.8	0.0	0.0	0.0		0.3	0.3 (0.1 - 0.9)
47	Malign	ant 1	neopla	sm of	f nasoj	phary	nx														
Males	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	3		
Rate	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	15.2	0.0	0.0		0.5	0.5 (0.2 - 1.7)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Persons	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	3		
Rate	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	6.2	0.0	0.0		0.2	0.3 (0.1 - 0.8)
148	Malign	ant 1	neopla	asm of	f hypo	phary	'nx														
Males	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	4		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	5.6	6.9	0.0	15.2	0.0	0.0		0.7	0.8 (0.3 - 2.0)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Persons	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	4		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	2.9	3.4	0.0	6.2	0.0	0.0		0.3	0.4 (0.1 - 1.0)

Age Yr	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ 7	Total	CR	ASR 95% CI
149	Malign	ant 1	neopla	asm of	f other	and i	ill-defi	ned si	tes wi	thin tl	ne lip,	oral c	avity,	and p	haryn	X					
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	53.9		0.2	0.3 (0.0 - 1.9)
emales	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1		
late	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0		0.2	0.2 (0.0 - 1.4)
ersons	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	2		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	15.8		0.2	0.2 (0.0 - 0.7)
50	Malign	ant 1	neopla	asm of	f oesop	hagu	S														
I ales	0	0	0	0	0	0	0	0	0	3	0	2	3	3	4	2	4	0	21		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	8.3	16.9	20.7	34.8	30.3	116.4	0.0		3.4	3.6 (2.3 - 5.5)
emales	0	0	0	0	0	0	0	0	0	0	0	1	0	1	4	1	1	1	9		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	6.5	28.3	10.4	16.6	22.4		1.5	1.2 (0.6 - 2.4)
ersons	0	0	0	0	0	0	0	0	0	3	0	3	3	4	8	3	5	1	30		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	6.4	8.6	13.4	31.2	18.5	52.9	15.8		2.5	2.3 (1.6 - 3.4)
51	Malign	ant 1	neopla	asm of	f stom	ach															
I ales	0	0	0	0	0	0	0	3	1	4	1	5	3	2	6	2	4	7	38		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	2.1	8.5	2.9	20.8	16.9	13.8	52.1	30.3	116.4	377.2		6.2	6.9 (5.0 - 9.5)
emales	0	0	0	0	0	1	0	1	1	2	0	3	1	2	3	3	6	5	28		
Rate	0.0	0.0	0.0	0.0	0.0	1.9	0.0	2.0	2.1	4.3	0.0	13.2	5.9	13.1	21.3	31.1	99.9	112.2		4.6	3.6 (2.5 - 5.2)
ersons	0	0	0	0	0	1	0	4	2	6	1	8	4	4	9	5	10	12	66		
late	0.0	0.0	0.0	0.0	0.0	1.0	0.0	4.0	2.1	6.4	1.5	17.1	11.5	13.4	35.1	30.8	105.9	190.1		5.4	4.9 (3.7 - 6.1)

Age Yr	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI
152	Malign	ant	neopla	asm of	small	intes	tine, i	ncludi	ng du	odenu	m										
Males	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0	0	0	0	4		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.0	5.6	6.9	0.0	0.0	0.0	0.0		0.7	0.7 (0.3 - 1.9)
Females	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	4		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	6.5	0.0	0.0	0.0	44.9		0.7	0.7 (0.2 - 1.7)
Persons	0	0	0	0	0	0	0	0	0	0	2	0	2	2	0	0	0	2	8		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	5.8	6.7	0.0	0.0	0.0	31.7		0.7	0.7 (0.4 - 1.5)
153	Malign	antı	neopla	asm of	colon	l															
Males	0	0	0	0	0	0	0	0	4	4	4	6	14	13	15	4	5	3	72		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.4	8.5	11.7	24.9	78.9	89.7	130.3	60.6	145.5	161.6		11.8	13.2 (10.1 - 16.2)
Females	0	0	0	0	0	0	1	0	2	3	6	4	8	7	9	8	11	4	63		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	4.1	6.4	18.3	17.6	47.0	45.7	63.8	82.8	183.1	89.8		10.4	9.1 (6.8 - 11.3)
Persons	0	0	0	0	0	0	1	0	6	7	10	10	22	20	24	12	16	7	135		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	6.2	7.4	14.9	21.4	63.3	67.1	93.7	73.8	169.4	110.9		11.1	11.0 (9.2 - 12.9)
154	Malign	antı	neopla	asm of	rectu	m, re	ctosig	moid j	unctio	on, and	d anus										
Males	0	0	0	0	1	0	0	0	3	0	4	7	6	10	10	5	2	4	52		
Rate	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	6.3	0.0	11.7	29.1	33.8	69.0	86.9	75.8	58.2	215.5		8.5	9.5 (6.9 - 12.1)
Females	0	0	0	0	0	0	0	1	1	1	0	3	3	1	3	6	2	3	24		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	2.1	2.1	0.0	13.2	17.6	6.5	21.3	62.1	33.3	67.3		3.9	3.3 (2.2 - 5.0)
Persons	0	0	0	0	1	0	0	1	4	1	4	10	9	11	13	11	4	7	76		
Rate	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.0	4.2	1.1	6.0	21.4	25.9	36.9	50.7	67.7	42.4	110.9		6.2	6.2 (4.8 - 7.6)

Age Yr	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ 7	Fotal	CR	ASR 95% CI
155	Malign	ant 1	neopla	asm of	liver	and i	ntrahe	patic	bile dı	ucts											
Males	0	0	0	0	0	0	0	0	0	3	0	0	1	5	1	3	0	0	13		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	5.6	34.5	8.7	45.5	0.0	0.0		2.1	2.3 (1.3 - 3.9)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	0	4		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	14.2	0.0	16.6	0.0		0.7	0.6 (0.2 - 1.5)
Persons	0	0	0	0	0	0	0	0	0	3	0	0	1	6	3	3	1	0	17		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	2.9	20.1	11.7	18.5	10.6	0.0		1.4	1.4 (0.9 - 2.2)
.56	Malign	ant 1	neopla	asm of	gall b	oladde	er and	extra	hepati	c bile	ducts										
/Iales	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1	3	0	7		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	4.2	0.0	0.0	8.7	15.2	87.3	0.0		1.1	1.1 (0.5 - 2.3)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	2	1	7		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	14.2	10.4	33.3	22.4		1.2	0.9 (0.4 - 1.8)
Persons	0	0	0	0	0	0	0	0	0	0	1	1	0	1	3	2	5	1	14		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	2.1	0.0	3.4	11.7	12.3	52.9	15.8		1.1	1.0 (0.6 - 1.6)
157	Malign	ant 1	neopla	asm of	panc	reas															
Males	0	0	0	0	0	0	0	0	0	1	1	3	5	3	8	4	4	4	33		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	2.9	12.5	28.2	20.7	69.5	60.6	116.4	215.5		5.4	6.2 (4.4 - 8.7)
Females	0	0	0	0	0	0	0	0	0	2	0	0	4	4	4	3	7	4	28		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	23.5	26.1	28.3	31.1	116.5	89.8		4.6	3.9 (2.7 - 5.6)
Persons	0	0	0	0	0	0	0	0	0	3	1	3	9	7	12	7	11	8	61		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	1.5	6.4	25.9	23.5	46.8	43.1	116.5	126.8		5.0	4.8 (3.6 - 6.1)

Age Yr	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ T	otal	CR	ASR 95% CI
158	Malign	ant 1	neopla	asm of	f retro	perito	neum	and p	eritor	neum											
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.1	0.0		0.2	0.1 (0.0 - 1.0)
emales	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	2		
late	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	6.5	0.0	0.0	0.0	0.0		0.3	0.4 (0.1 - 1.5)
ersons	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	3		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	3.4	0.0	0.0	10.6	0.0		0.2	0.2 (0.1 - 0.7)
59	Malign	ant 1	neopla	asm of	f other	and i	ill-defi	ned si	tes wi	thin th	ne dige	stive	organ	s and	perito	neum					
Iales	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	0	0	4		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	4.2	0.0	0.0	0.0	30.3	0.0	0.0		0.7	0.6 (0.2 - 1.6)
emales	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.6	0.0		0.2	0.1 (0.0 - 0.6)
ersons	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	1	0	5		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	2.1	0.0	0.0	0.0	12.3	10.6	0.0		0.4	0.3 (0.1 - 0.8)
60	Malign	ant 1	neopla	asm of	f nasal	cavit	ies, m	iddle 6	ear, ar	nd acco	essory	sinus	es								
I ales	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0		0.2	0.2 (0.0 - 1.2)
emales	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
ersons	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0		0.1	0.1 (0.0 - 0.6)

Age Yr	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI
161	Malign	ant 1	neopla	sm of	laryn	X															
Males	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	3	1	1	9		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.3	6.9	8.7	45.5	29.1	53.9		1.5	1.7 (0.9 - 3.3)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Persons	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	3	1	1	9		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	3.4	3.9	18.5	10.6	15.8		0.7	0.7 (0.4 - 1.4)
162	Malign	ant 1	neopla	sm of	f trach	ea, bı	onchi	ıs, and	d lung												
Males	0	0	0	0	0	0	0	0	3	8	6	16	14	19	22	18	17	5	128		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	16.9	17.6	66.5	78.9	131.0	191.2	272.8	494.8	269.4		20.9	22.4 (18.5 - 26.3)
Females	0	0	0	0	0	0	0	2	1	5	4	8	2	9	17	10	7	6	71		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	2.1	10.7	12.2	35.2	11.7	58.8	120.4	103.5	116.5	134.7		11.7	10.0 (7.6 - 12.3)
Persons	0	0	0	0	0	0	0	2	4	13	10	24	16	28	39	28	24	11	199		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	4.2	13.8	14.9	51.3	46.0	93.9	152.2	172.2	254.2	174.3		16.3	15.6 (13.4 - 17.7)
163	Malign	ant 1	neopla	sm of	f pleur	a															
Males	0	0	0	0	0	0	0	1	0	0	0	1	2	1	2	0	0	0	7		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	4.2	11.3	6.9	17.4	0.0	0.0	0.0		1.1	1.3 (0.6 - 2.7)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Persons	0	0	0	0	0	0	0	1	0	0	0	1	2	1	2	0	0	0	7		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	2.1	5.8	3.4	7.8	0.0	0.0	0.0		0.6	0.6 (0.3 - 1.3)

Age Yrs	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ 1	Total	CR	ASR 95% CI
164	Malign	ant 1	neopla	asm of	thym	us, he	art, a	nd me	diasti	num											
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0		0.2	0.2 (0.0 - 1.4)
Persons	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0		0.1	0.1 (0.0 - 0.7)
170	Malign	ant 1	neopla	asm of	bone	and a	rticul	ar car	tilage												
Males	0	0	0	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	3		
Rate	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	2.1	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	0.0		0.5	0.5 (0.2 - 1.5)
Females	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.2	0.1 (0.0 - 0.9)
Persons	0	0	0	0	0	1	0	0	1	1	0	0	0	1	0	0	0	0	4		
Rate	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.1	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0		0.3	0.3 (0.1 - 0.8)
171	Malign	ant 1	neopla	asm of	conn	ective	and o	ther s	oft tis	sue											
Males	0	0	0	0	2	0	0	0	1	0	0	0	0	0	2	0	0	0	5		
Rate	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	17.4	0.0	0.0	0.0		0.8	0.7 (0.3 - 1.7)
Females	0	0	0	0	0	1	0	0	0	0	1	0	0	1	0	1	1	0	5		
Rate	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	3.0	0.0	0.0	6.5	0.0	10.4	16.6	0.0		0.8	0.7 (0.3 - 1.7)
Persons	0	0	0	0	2	1	0	0	1	0	1	0	0	1	2	1	1	0	10		
Rate	0.0	0.0	0.0	0.0	1.6	1.0	0.0	0.0	1.0	0.0	1.5	0.0	0.0	3.4	7.8	6.2	10.6	0.0		0.8	0.7 (0.4 - 1.3)

Age Yr	es 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	CR	ASR 95% CI
172	Malig	nant	melan	oma o	f skin	l															
Males	0	0	0	0	0	0	1	1	0	2	3	0	2	1	1	4	2	3	20		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	1.9	2.0	0.0	4.2	8.8	0.0	11.3	6.9	8.7	60.6	58.2	161.6		3.3	3.5 (2.2 - 5.4)
Females	0	0	0	0	0	0	0	2	2	2	2	0	1	3	2	2	1	0	17		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	4.1	4.3	6.1	0.0	5.9	19.6	14.2	20.7	16.6	0.0		2.8	2.4 (1.5 - 3.9)
Persons	0	0	0	0	0	0	1	3	2	4	5	0	3	4	3	6	3	3	37		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	1.0	3.0	2.1	4.3	7.5	0.0	8.6	13.4	11.7	36.9	31.8	47.5		3.0	2.7 (2.0 - 3.8)
173	Other	mali	gnant	neopl	asm o	f skin															
Males	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	3		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	8.7	0.0	29.1	0.0		0.5	0.5 (0.2 - 1.5)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4		0.2	0.1 (0.0 - 0.8)
Persons	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	4		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	3.9	0.0	10.6	15.8		0.3	0.3 (0.1 - 0.8)
174	Malig	nant	neopla	asm of	fema	le bre	ast														
Females	0	0	0	0	0	0	2	2	6	16	21	17	18	17	8	10	17	11	145		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	3.9	4.0	12.3	34.2	63.9	74.7	105.7	111.1	56.7	103.5	283.0	246.9		23.8	21.8 (18.3 - 25.4)
180	Malig	nant 1	neopla	asm of	cervi	x utei	i														
Females	0	0	0	0	0	2	0	0	3	1	3	2	0	0	3	1	1	1	17		
Rate	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	6.2	2.1	9.1	8.8	0.0	0.0	21.3	10.4	16.6	22.4		2.8	2.3 (1.5 - 3.8)

Age Yr	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ 7	Fotal	CR	ASR 95% CI
182	Malign	ant 1	neopla	asm of	body	of ute	erus														
Females	0	0	0	0	0	0	0	0	0	0	2	2	1	1	2	3	2	0	13		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	8.8	5.9	6.5	14.2	31.1	33.3	0.0		2.1	1.8 (1.1 - 3.2)
183	Malign	ant 1	1eopla	asm of	ovary	and	other	uterin	e adn	exa											
Females	0	0	0	0	0	0	0	1	1	4	5	4	4	1	3	4	3	0	30		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	2.1	8.5	15.2	17.6	23.5	6.5	21.3	41.4	49.9	0.0		4.9	4.4 (3.1 - 6.4)
184	Malign	ant 1	neopla	asm of	other	and i	unspe	cified 1	female	e genit	al orga	ans									
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	10.4	0.0	0.0		0.3	0.2 (0.1 - 1.0)
185	Malign	ant 1	1eopl a	asm of	prost	ate															
Males	0	0	0	0	0	0	0	0	0	2	0	2	6	13	20	12	17	15	87		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	8.3	33.8	89.7	173.8	181.9	494.8	808.2		14.2	16.4 (13.0 - 19.9)
186	Malign	ant 1	neopla	asm of	testis						_										
Males	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.2	0.2 (0.0 - 1.1)

Age Yrs 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Total CR ASR 95% CI

187	Malign	ant n	eoplas	sm of	penis	and o	ther n	nale ge	enital	organs	5										
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	53.9		0.2	0.3 (0.0 - 1.9)
188	Malign	ant n	eoplas	sm of	bladd	er															
Males	0	0	0	1	0	0	0	0	0	1	1	1	0	7	6	5	4	2	28		
Rate	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	2.1	2.9	4.2	0.0	48.3	52.1	75.8	116.4	107.8		4.6	5.0 (3.4 - 7.2)
Females	0	0	0	0	0	0	0	0	0	0	0	0	1	3	1	2	1	2	10		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	19.6	7.1	20.7	16.6	44.9		1.6	1.5 (0.8 - 2.7)
Persons	0	0	0	1	0	0	0	0	0	1	1	1	1	10	7	7	5	4	38		
Rate	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.1	1.5	2.1	2.9	33.5	27.3	43.1	52.9	63.4		3.1	3.0 (2.2 - 4.1)
189	Malign	ant n	eoplas	sm of	kidne	y and	other	and u	nspec	ified u	rinar	y orga	ns								
Males	0	0	0	0	0	0	0	1	2	2	1	2	2	3	3	6	2	0	24		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	4.2	4.2	2.9	8.3	11.3	20.7	26.1	90.9	58.2	0.0		3.9	3.9 (2.6 - 5.8)
Females	0	0	0	0	0	0	0	0	0	0	1	0	2	1	3	3	4	0	14		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	11.7	6.5	21.3	31.1	66.6	0.0		2.3	1.9 (1.1 - 3.2)
Persons	0	0	0	0	0	0	0	1	2	2	2	2	4	4	6	9	6	0	38		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	2.1	2.1	3.0	4.3	11.5	13.4	23.4	55.4	63.5	0.0		3.1	2.8 (2.1 - 3.9)

Age Yrs 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Total CR ASR 95% CI

190	Malign	ant n	eopla	sm of	eye																
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Females	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	3		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	14.2	0.0	0.0	0.0		0.5	0.4 (0.1 - 1.4)
Persons	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	3		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	7.8	0.0	0.0	0.0		0.2	0.2 (0.1 - 0.7)
191	Malign	ant n	eopla	sm of	brain																
Males	0	1	1	1	1	1	1	1	2	1	3	2	2	4	5	2	1	1	30		
Rate	0.0	2.2	2.2	2.0	1.6	1.9	1.9	2.0	4.2	2.1	8.8	8.3	11.3	27.6	43.4	30.3	29.1	53.9		4.9	5.1 (3.6 - 7.3)
Females	0	0	0	0	0	0	1	3	4	2	2	4	0	1	2	1	1	0	21		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	2.0	6.0	8.2	4.3	6.1	17.6	0.0	6.5	14.2	10.4	16.6	0.0		3.5	2.9 (1.9 - 4.4)
Persons	0	1	1	1	1	1	2	4	6	3	5	6	2	5	7	3	2	1	51		
Rate	0.0	1.1	1.1	1.0	0.8	1.0	1.9	4.0	6.2	3.2	7.5	12.8	5.8	16.8	27.3	18.5	21.2	15.8		4.2	3.9 (2.8 - 5.0)
192	Malign	ant n	eopla	sm of	other	and u	nspec	ified p	arts o	f nerv	ous sy	stem									
Males	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.2	0.1 (0.0 - 0.9)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	16.6	0.0		0.3	0.2 (0.1 - 0.9)
Persons	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	3		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	3.9	0.0	10.6	0.0		0.2	0.2 (0.1 - 0.6)

Age Yr	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ 7	Γotal	CR	ASR 95% CI
193	Malign	ant 1	neopla	asm of	thyro	oid gla	nd														
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.7	0.0	0.0	0.0		0.2	0.2 (0.0 - 1.2)
Females	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
Persons	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0		0.1	0.1 (0.0 - 0.6)
194	Malign	ant i	neopla	asm of	other	endo	crine	glands	s and	related	l struc	tures									
Males	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1		
Rate	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.2	0.3 (0.0 - 1.9)
Females	1	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	4		
Rate	2.3	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	2.1	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.7	0.7 (0.3 - 1.9)
Persons	2	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	5		
Rate	2.2	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.1	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.4	0.5 (0.2 - 1.2)
199	Malign	ant 1	neopla	asm w	ithout	speci	ficatio	on of s	ite												
Males	0	0	0	0	0	1	0	0	3	3	2	8	7	13	7	7	3	6	60		
Rate	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	6.3	6.4	5.9	33.2	39.5	89.7	60.8	106.1	87.3	323.3		9.8	11.1 (8.3 - 14.0)
Females	0	0	0	0	0	1	1	0	1	3	3	4	2	1	6	7	10	8	47		
Rate	0.0	0.0	0.0	0.0	0.0	1.9	2.0	0.0	2.1	6.4	9.1	17.6	11.7	6.5	42.5	72.5	166.5	179.6		7.7	5.9 (4.4 - 7.9)
Persons	0	0	0	0	0	2	1	0	4	6	5	12	9	14	13	14	13	14	107		
Rate	0.0	0.0	0.0	0.0	0.0	1.9	1.0	0.0	4.2	6.4	7.5	25.6	25.9	47.0	50.7	86.1	137.7	221.8		8.8	8.4 (6.8 - 9.9)

Age Yr	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ 7	Γotal	CR	ASR 95% CI
200	Lymph	osar	coma	and r	eticul	osarco	oma														
Males	0	0	0	0	0	0	0	2	0	0	4	1	0	4	4	3	3	1	22		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	0.0	11.7	4.2	0.0	27.6	34.8	45.5	87.3	53.9		3.6	3.7 (2.4 - 5.6)
Females	0	0	0	0	0	0	0	0	0	2	1	3	1	3	6	4	3	4	27		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	3.0	13.2	5.9	19.6	42.5	41.4	49.9	89.8		4.4	3.7 (2.6 - 5.4)
Persons	0	0	0	0	0	0	0	2	0	2	5	4	1	7	10	7	6	5	49		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	2.1	7.5	8.5	2.9	23.5	39.0	43.1	63.5	79.2		4.0	3.7 (2.8 - 4.9)
201	Hodgk	in's c	liseas	e																	
Males	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0	3		
Rate	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.5	0.4 (0.1 - 1.3)
Females	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1		
Rate	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.2	0.2 (0.0 - 1.1)
Persons	0	0	0	0	1	1	0	0	0	0	2	0	0	0	0	0	0	0	4		
Rate	0.0	0.0	0.0	0.0	0.8	1.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.3	0.3 (0.1 - 0.8)
202	Other	malig	gnant	neopl	asms (of lym	phoid	and l	nistioc	ytic tis	ssue										
Males	0	0	1	0	0	0	0	0	0	1	1	1	1	2	3	2	3	2	17		
Rate	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	2.1	2.9	4.2	5.6	13.8	26.1	30.3	87.3	107.8		2.8	3.1 (1.9 - 5.0)
Females	0	0	0	0	0	1	0	0	1	1	1	0	0	5	2	0	0	1	12		
Rate	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	2.1	2.1	3.0	0.0	0.0	32.7	14.2	0.0	0.0	22.4		2.0	1.9 (1.1 - 3.4)
Persons	0	0	1	0	0	1	0	0	1	2	2	1	1	7	5	2	3	3	29		
Rate	0.0	0.0	1.1	0.0	0.0	1.0	0.0	0.0	1.0	2.1	3.0	2.1	2.9	23.5	19.5	12.3	31.8	47.5		2.4	2.3 (1.6 - 3.4)

Age Yrs	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ 7	Fotal	CR	ASR 95% CI
203	Multip	le my	yelom	a and	immu	inopr	olifera	itive n	eoplas	sms											
Males	0	0	0	0	0	0	0	0	1	1	1	2	0	2	2	2	2	2	15		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	2.1	2.9	8.3	0.0	13.8	17.4	30.3	58.2	107.8		2.4	2.6 (1.6 - 4.4)
emales	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	1	4	1	9		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	13.1	0.0	10.4	66.6	22.4		1.5	1.1 (0.6 - 2.1)
ersons	0	0	0	0	0	0	0	0	1	1	2	2	0	4	2	3	6	3	24		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.1	3.0	4.3	0.0	13.4	7.8	18.5	63.5	47.5		2.0	1.7 (1.2 - 2.6)
04	Lymph	oid l	eukae	emia																	
Males	1	0	0	0	0	0	0	0	1	2	0	0	3	1	1	2	1	1	13		
Rate	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	4.2	0.0	0.0	16.9	6.9	8.7	30.3	29.1	53.9		2.1	2.4 (1.4 - 4.2)
Females	1	0	0	1	0	0	0	0	0	0	2	0	0	0	0	0	1	1	6		
Rate	2.3	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	6.1	0.0	0.0	0.0	0.0	0.0	16.6	22.4		1.0	1.0 (0.4 - 2.1)
Persons	2	0	0	1	0	0	0	0	1	2	2	0	3	1	1	2	2	2	19		
Rate	2.2	0.0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	2.1	3.0	0.0	8.6	3.4	3.9	12.3	21.2	31.7		1.6	1.6 (1.0 - 2.5)
205	Myeloi	d leu	kaem	iia																	
Males	1	0	0	1	1	0	1	1	2	2	2	1	2	1	7	5	1	0	28		
Rate	2.2	0.0	0.0	2.0	1.6	0.0	1.9	2.0	4.2	4.2	5.9	4.2	11.3	6.9	60.8	75.8	29.1	0.0		4.6	4.6 (3.1 - 6.6)
Females	0	0	1	0	0	0	0	0	0	2	0	1	0	2	4	3	1	1	15		
Rate	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	4.4	0.0	13.1	28.3	31.1	16.6	22.4		2.5	2.1 (1.3 - 3.5)
Persons	1	0	1	1	1	0	1	1	2	4	2	2	2	3	11	8	2	1	43		
Rate	1.1	0.0	1.1	1.0	0.8	0.0	1.0	1.0	2.1	4.3	3.0	4.3	5.8	10.1	42.9	49.2	21.2	15.8		3.5	3.3 (2.4 - 4.4)

Age Yrs	s 0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ T	otal	CR	ASR 95% CI
208	Leukae	emia	of un	specif	ied cel	ll type	<u>}</u>														
Males	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				
emales	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1		
Rate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4		0.2	0.1 (0.0 - 0.8)
ersons	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.8		0.1	0.1 (0.0 - 0.6)
38	Neopla	sm o	f unce	ertain	behav	viour (of oth	er and	unsp	ecified	sites a	and ti	ssues								
Iales	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
emales	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4		0.2	0.1 (0.0 - 0.8)
ersons	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.8		0.1	0.1 (0.0 - 0.6)
73	Disord	ers o	f plas	ma pr	otein	metab	olism														
I ales	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			
emales	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2		
ate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.6	22.4		0.3	0.2 (0.0 - 0.8)
ersons	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2		
late	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.6	15.8		0.2	0.1 (0.0 - 0.5)

TERMINOLOGY USED

Age-Specific Rates are calculated by dividing the number of cases in each five year (four year for mortality) age groups and sex stratum by the ABS population estimate for that stratum and multiplying the product by 100,000 to give the rates per 100,000 for all age groups.

Age-Standardised Rates (ASR). This is the rate that would theoretically have been observed if the population had the standard world age distribution. It is calculated by first estimating the age-specific rates and then applying these rates to the reference population. The reference population used in this publication was the World Standard Population.

Cancer Incidence is defined as the number of new cases of cancer diagnosed in a given population during a specified time period. The incidence data in this report are based on the cancer cases in ACT residents notified to the registry between 1 January 1994 and 31 December 1998.

Cancer Mortality is defined as the number of cancer deaths in a given population occurring in a given time period and who resided in the ACT at the time of diagnosis. The death may have occurred outside of the ACT. For this reason, mortality information in this report is not directly comparable with death data released from the Australian Bureau of Statistics (ABS) where it is based on residence at the time of death.

Cases are individual cancers. A person may have more than one cancer giving rise to multiple cases in the same person. Second cases in one person are only counted if they are of a different cell type or originate in a different organ.

95% Confidence Intervals is a range of values for a rate which has a specified probability of including the true value of the rate.

Crude Rates are obtained by dividing the number of cases in a given population by that population and multiplying by 100,000.

Crude Rates can give some indication of the disease burden of cancer on a population. Since the incidences of several types of cancer are age dependent, crude rates are inappropriate for comparisons between sexes or across time.

IARC is the International Agency for Research on Cancer

Lifetime Risk is the risk a person will develop or die from cancer during their lifetime. It assumes the person remains at risk until the age of 75 years.

Site is the place where the cancer occurs.

REFERENCES

- 1. Cancer Series Number 15, *Cancer in Australia* 1997. Incidence and mortality data for 1997 and selected data for 1998 and 1999, November 2000, AIHW and AACR
- 2. Health Series Number 19, Health Risk Factors in the ACT 1998. Epidemiology Unit, Population Health, ACT Department of Health and Community Care. October 1998 Carol Kee, Michelle Peterson, Kate Rockpool.
- 3. ABS, Australian Capital Territory in Focus 1997, Catalogue No.1307.8
- 4. ABS, Australian Demographic Trends 1997, Catalogue No. 3102.0
- 5. ABS, Australian Capital Territory in Focus 1994, Catalogue No. 1307.8
- 6. ABS, Births Australia 1996, Catalogue. No. 3301.0
- 7. Bourne Maureen, *Health Series Number 25 ACT Maternal and Perinatal 1997 Tables*, Clinical Epidemiology and Health Outcomes Centre, Population Health, Department of Health and Community Care. March 2000
- 8. ABS, Australian Demographic Trends 1997, Catalogue No. 3102.0
- 9. ABS, Census of Population and Housing, Selected Social and Housing Characteristics for Statistical Local Areas, ACT, 1996 Catalogue No. 2015.8
- 10. Gilbert C, White U, ACT's Health: A report on the health status of ACT residents, Health Series No. 1, Epidemiology Unit, Department of Health and Community Care, October 1995
- 11. Carla Cranny and Associates, Professor Peter Castaldi AO. Integrated Cancer Care in the ACT. Report for the ACT Department of Health and Community Care. Draft for Comment, June 1999.